Establishment and Clinical Application of AI-based Multimodal Diagnosis System for Ovarian Tumors
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 584
- 主要终点
- Pathological diagnosis
研究概览
简要总结
Ovarian tumors are a common disease that threatens women's health. They are insidious in onset, have over ten pathological types, and exhibit diverse biological behaviors, making accurate diagnosis a key factor in clinical decision-making and improving prognosis. Introducing AI technology to establish an auxiliary diagnosis system composed of multi-dimensional clinical data, including medical imaging and tumor markers, will greatly enhance diagnosis efficiency by predicting the pathological types of common ovarian tumors.
Our research group has innovatively developed an AI-based ultrasound intelligent auxiliary diagnosis software for ovarian tumors, which has been clinically validated to be effective. This project will build on this by: (1) utilizing a wealth of multi-center retrospective clinical data to combine ultrasound, MRI images, physiological, pathological, and laboratory data to form the first multi-modal ovarian tumor public dataset supporting AI tasks; (2) using convolutional neural network technology to realize multi-modal image multi-classification intelligent recognition on this dataset based on surgical pathology as the standard, and then fuse features at the level of clinical data with the intelligent recognition model to train and validate an auxiliary diagnosis model for predicting the top ten pathological types of ovarian tumors; (3) applying privacy computing and federated learning methods to conduct multi-center, prospective validation and optimization of the above model, ultimately forming a clinical auxiliary diagnosis system that can predict the pathological types of most ovarian tumors and apply it to clinical practice.
详细描述
Methods/Design Study Aim The first objective of this study are to construct a multimodal ovarian tumor public dataset that includes ultrasound, MRI images, and clinical indicator data to support AI-driven tasks. This dataset will integrate diverse types of medical data to facilitate comprehensive AI analysis and model training. By employing convolutional neural network (CNN) technology, the study seeks to achieve intelligent multiclass recognition of multimodal images. This involves extracting and analyzing features from imaging data and integrating them with multidimensional clinical data at the feature level, with the goal of training and validating an auxiliary diagnostic model capable of accurately predicting at least the ten most common pathological types of ovarian tumors. Additionally, the study will utilize privacy-preserving computing and federated learning methods to conduct multicenter, prospective optimization and validation of the model. These methods will ensure data security and privacy while enabling collaborative model training. The ultimate goal is to develop a clinical auxiliary diagnostic system that can predict the pathological types of most ovarian tumors and be implemented in clinical settings. This comprehensive approach aims to leverage the strengths of AI technology in medical imaging, ensuring data security while enhancing the accuracy and reliability of ovarian tumor diagnosis.
Study Setting This study is conducted in Beijing, China. The study subjects are sourced from Beijing Shijitan Hospital, Beijing Friendship Hospital, and Beijing Obstetrics and Gynecology Hospital, all of which are affiliated with Capital Medical University. These hospitals provide a diverse patient population, which supports the generalizability of the study findings.
Study Subjects The study subjects are patients diagnosed with ovarian tumors who have undergone surgical treatment. The cases used for developing the predictive model are sourced from patients who were consecutively enrolled between January 2018 and January 2023. Clinical application validation cases will be prospectively collected from patients between June 2023 and June 2025. The inclusion criteria for both parts of the study are as follows: (1) patients diagnosed with ovarian tumors who have undergone surgical treatment; (2) patients with complete imaging data (ultrasound or MRI) and tumor marker results obtained within three months prior to surgery. Additionally, the second part requires informed consent from the participants. The exclusion criteria are as follows: (1) patients with surgical pathology not originating from the ovary; (2) duplicate cases; (3) patients who have received chemotherapy or radiotherapy; (4) recurrent cases; (5) poor-quality imaging of ovarian lesions; and (6) incomplete case information.
Ethics The study protocol has been reviewed and approved by the Ethics Committee of Beijing Shijitan Hospital, affiliated with Capital Medical University. The ethics approval number is: [provide number]. The study will be conducted in accordance with the principles of the Declaration of Helsinki. For the model development phase, retrospective cases have been granted a waiver of informed consent. For the clinical validation phase, all participants will read an informed consent form before the study begins, voluntarily agree to participate, and sign the informed consent form.
Data Collection The investigators will collect imaging data (pelvic ultrasound, pelvic MRI) and clinical data (general information, medical history, family history, physical examination, laboratory tests, pathology reports, clinical diagnosis, etc.) from the study subjects. This will help construct a multimodal ovarian tumor dataset with classification and segmentation annotations, providing AI dataset support for the subsequent development of multimodal ovarian tumor auxiliary diagnostic models. As the research progresses, the investigators aim to achieve flexible expansion and deep mining of the dataset, establish standardized protocols for multimodal datasets, and enable effective data sharing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Continuous cases admitted for diagnosis of ovarian tumor and preparation for surgical treatment;
- •Complete imaging data (ultrasound or MRI) and tumor marker results within 3 months before surgery;
- •Voluntarily sign informed consent.
排除标准
- •Patients with non-ovarian origin tumor as surgical pathology;
- •Repetitive cases;
- •Cases receiving radiotherapy and chemotherapy;
- •Recurrent cases;
- •Poor image quality of ovarian lesions;
结局指标
主要结局
Pathological diagnosis
时间窗: Within one week postoperatively
After the surgical specimen is delivered to the pathology department, the pathologist conducts a gross examination, recording the size, shape, surface characteristics, and cut surface features of the specimen (e.g., the proportion of solid and cystic components of the tumor). The specimen is then processed according to standard protocols to prepare tissue sections, which are subsequently stained. Once staining is complete, the slides are independently examined under a microscope by two pathologists, who evaluate the tumor cell morphology, arrangement, and histological characteristics to determine the pathological nature (benign, borderline, or malignant) and type of the tumor. If there is a discrepancy in the diagnoses, the case is referred to a senior pathologist for review, whose final opinion shall prevail.
AUC (Area Under the ROC Curve)
时间窗: All study subjects must complete follow-up within one year after postoperative pathological diagnosis.
In this study, the area under the curve (AUC) is used as the primary evaluation metric to quantify the diagnostic performance of the new prediction model. AUC is based on the receiver operating characteristic (ROC) curve and evaluates the model's ability to distinguish between positive and negative cases at various thresholds by comparing the model's predictions with the gold standard (pathological diagnosis). Significance of AUC: The AUC value ranges from 0.5 to 1.0, with higher values indicating stronger overall discriminative ability of the model. Specific interpretations are as follows: AUC = 0.5: The model has no diagnostic capability. 0.7 ≤ AUC \< 0.9: The model demonstrates good diagnostic performance. AUC ≥ 0.9: The model shows excellent diagnostic performance. AUC \< 0.7: The model's diagnostic capability is considered low. By calculating the AUC value of the new prediction model, this study assesses its ability to distinguish positive cases from negative cases, thereby verif
次要结局
未报告次要终点
